Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Oric Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204047
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $31,437 | $24,640 |
| General and administrative | 8,182 | 8,078 |
| Total operating expenses | 39,619 | 32,718 |
| Loss from operations | (39,619) | (32,718) |
| Other income, net | 3,852 | 2,697 |
| Net loss | $(35,767) | $(30,021) |
| Other comprehensive loss: |
Item 1. Financial Statements.
FAQ
- What is Oric Pharmaceuticals, Inc.'s R&D?
- Oric Pharmaceuticals, Inc. (ORIC) reported R&D of $31.44M in Q1 2026.
- How has Oric Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Oric Pharmaceuticals, Inc.'s R&D increased by 27.6% year-over-year, from $24.64M to $31.44M.
- What is the long-term trend for Oric Pharmaceuticals, Inc.'s R&D?
- Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s R&D has grown at a 17.9% compound annual growth rate (CAGR), from $56.86M to $109.82M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Oric Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude